Search
Menu
Home
HTB
2014
February
HTB
February 2014
Contents
Editorial
January/February 2014: Volume 15 Number 1/2
Conference reports
4th International Workshop on HIV & Women, 13-14 January 2014, Washington
Women, HIV research and antiretrovirals
Improved virological outcomes for women starting efavirenz-based first-line regimens in South Africa
High rates of pregnancy in HIV positive women in Zambia and South Africa
Contraceptive choices among a Canadian cohort of HIV positive women
Bone disease and older HIV positive women
Lower immune response to the qHPV vaccine in HIV positive girls
HIV exposed vs unexposed babies have lower gestational age and birth weight in Danish study
Outcomes in infants exposed to lopinavir/ritonavir in utero
17th International Conference on AIDS and STIs in Africa (ICASA), 7-11 December 2013, Cape Town
Two percent rate of efavirenz discontinuation in an ART programme in Malawi
6th International Workshop on HIV Persistence During Therapy, 3-6 December 2013, Miami, USA
Report from the 6th Workshop on HIV Persistence
Antiretrovirals
Dolutegravir approved in Europe
Treatment access
BMS to add atazanavir to Patent Pool
Donors pledge $12 billion to Global Fund for 2014–2016: increase still short of $15 billion goal
Global Fund and UNAIDS urge Nigeria to reconsider new anti-gay law
Pregnancy
Data from two cases of rilpivirine use in pregnancy
Guidelines
BHIVA update adult ARV guidelines (November 2013)
Hepatitis coinfection
EASL update guidelines for treatment of hepatitis C (2013)
Sofosbuvir approved in the US and Europe for HCV genotypes 1-6
Simeprevir approved in the US
Fair Pricing Coalition criticises cost of new HCV drugs
Boehringer Ingelheim stops development of deleobuvir for HCV
TB coinfection
EMA recommends conditional approval of bedaquiline for drug resistant TB with orphan drug status
Cure-related research
HIV rebounds in Boston stem cell transplant recipients
On the web
Online journals
Community publications and reports
PDFs
Volume 15 Number 1/2 January/February 2014 PDF
HTB RSS
Early access
Lenacapavir submitted to the US FDA with an indication for HIV PrEP
20 December 2024
i-Base guides updated online
5 December 2024
All early access reports
Current issues
December 2024
November 2024
October 2024
Back issues
Special report
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate